Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.

Trial Profile

Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2013

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2012 Results presented at the34th Annual Meeting of the American Society for Bone and Mineral Research.
    • 15 Oct 2012 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met.
    • 20 Sep 2011 Interim results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top